In addition, in vitro experiments verified that sorafenib inhibited the expression of RRM2 in HCC cells, which was positively correlated with the anticancer activity of sorafenib, proving that RRM2 is a new molecular target of sorafenib in HCC cells (Yang, Lin & Liu, 2020). The gene discussed is RRM2; the disease is hepatocellular carcinoma.